Open Therapeutics Gains Antitumor Drug For Inhibiting Cancerous Tumors
Open Therapeutics announces licensing a new class of anticancer drugs from Nationwide Children’s Hospital. The drug, amphiphilic amines (RCn), shows promise against mouse models of cancer, including pediatric and adult sarcomas, lymphoma, and neuroblastoma. A derivative of RCn, RC16, is approximately ten times more effective against the tumor cells than healthy cells. As shown with in vivo studies, RCn enhances the effectiveness of approved anticancer chemotherapy drugs etoposide, doxorubicin, and paclitaxel by acting as a nanocarrier....